Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

Table 4 Overall quantitative analysis of reticulocyte counts (×10⁹/L) and serum iron percentage reduction

Analysis	Formulation A N= 17	Formulation B N= 16	p (Mann-Whitney's U test)
Reticulocyte counts (×10⁹/L)
Mean	2.7 ± 2.9	2.6 ± 2.7	0.678
Maximum	4.3 ± 3.9	3.9 ± 3.9	0.397
T(Rmax) (hours)	146.8 ± 59.9	130.5 ± 51.8	0.201
Serum iron percentage reduction
Mean	39.8 ± 18.4	26.5 ± 13.1	0.265
Maximum	47.3 ± 19.2	39.2 ± 15.2	0.355
T(Rmax) (hours)	160.9 ± 61.6	148.5 ± 53.5	0.365

Data are reported as mean ± standard deviation.
These data correspond to the 34 patients who received one of the EPO formulations.
T(Rmax): Time to reach maximum response.

ISSN: 1471-2369